The discovery that SHP2 can dephosphorylate even mutant GTP-bound Ras in tumor cells and release Ras from its inactive state establishes SHP2 as a novel drug target that could be effective in Ras-driven human cancer. Here, PTPN11 is linked to neoplasm.